▶ GHRP-2 · SUBTOPIC · DOSING LITERATURE

GHRP-2 Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of GHRP-2. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for GHRP-2 reports the following route(s) of administration: Subcutaneous (research), Intranasal (Japan diagnostic). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of GHRP-2.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for GHRP-2 of approximately ~15-60 minutes. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of GHRP-2. Refer to the original publication for full protocol detail.

Bowers CY, Reynolds GA, Durham D, et al. (2001) reports the GHRP-2 protocol used in Growth hormone-releasing peptide-2: A diagnostic agent for pediatric GH deficiency, published in Endocrine. See the source for the protocol-level dose range, frequency, and duration. link
Smith RG, Van der Ploeg LH, Howard AD, et al. (1997) reports the GHRP-2 protocol used in Pharmacology and effects of growth hormone-releasing peptides, published in Endocr Rev. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What is the half-life of GHRP-2?

Approximately 15-60 minutes plasma half-life. Multiple daily administrations are needed for sustained GH-axis stimulation in research protocols.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · 4 °C 24 months

Reconstituted · 2-8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research-use only in the United States.

WADA · Prohibited at all times under WADA Section S2 (growth-hormone-secretagogue sub-category).

◀ GHRP-2 OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-25